Vicplas International Sees Swing to Loss in FY24 on Lackluster Medical Device Unit

MT Newswires09-25

Vicplas International (SGX:569), a medical devices and pipes manufacturer, expects to record a consolidated loss after tax of less than SG$1.8 million for the financial year ended July 31, 2024, reversing a S$4.2 million profit the previous year, according to a Tuesday filing on the Singapore Exchange.

The loss is being attributed to challenges in its medical devices segment, including lower sales as customers adjusted post-pandemic inventory levels, and higher costs linked to its Changzhou plant expansion and the startup of a new facility in Juarez, Mexico.

Despite this, the group's adjusted EBITDA is expected to remain positive, between SG$6.5 million and SG$7.5 million, compared to SG$14.7 million last year, supported by its pipes and pipe fittings segment.

Price (SGD): S$0.10, Change: S$+0.0010, Percent Change: +1.04%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment